Literature DB >> 11215520

The role of ras and other low molecular weight guanine nucleotide (GTP)-binding proteins during hematopoietic cell differentiation.

J S Scheele1, D Ripple, M Lübbert.   

Abstract

Recent progress in the understanding of signal transduction and gene regulation in hematopoietic cells has shown that many intracellular signalling pathways are modulated by low molecular weight guanine nucleotide (GTP)-binding proteins (LMWGs). LMWGs act as molecular switches for regulating a wide range of signal-transduction pathways in virtually all cells. In hematopoietic cells, LMWGs have been shown to participate in essential functions such as growth control, differentiation, cytoskeletal organization, cytokine and chemoattractant-induced signalling events, reduced nicotinamide adenine dinucleotide phosphate oxidase activity, intracellular vesicle transport and secretion. In human leukemias, myelodysplastic syndromes and myeloproliferative disorders, Ras activation occurs by point mutations, overexpression or by alteration of NF-1 Ras-GTPase activating protein (GAP). These are postinitiation events in leukemia but may modulate growth-factor-dependent and independent leukemic growth. Two animal models of mutated N-ras expression resulting in myelodysplastic and myeloproliferative features are discussed. The role of Ras in organ development is discussed in the context of transgenic knockout mice. More LMWG functions will certainly be identified as we gain a better understanding of regulatory pathways modulating myeloid signal transduction. This review will summarize our current understanding of this rapidly advancing area of research.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11215520     DOI: 10.1007/pl00000675

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  7 in total

1.  Ral is both necessary and sufficient for the inhibition of myeloid differentiation mediated by Ras.

Authors:  Nader Omidvar; Lorna Pearn; Alan K Burnett; Richard L Darley
Journal:  Mol Cell Biol       Date:  2006-05       Impact factor: 4.272

2.  RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.

Authors:  Won-Il Kim; Ilze Matise; Miechaleen D Diers; David A Largaespada
Journal:  Blood       Date:  2008-10-24       Impact factor: 22.113

3.  Overexpression of Rheb2 enhances mouse hematopoietic progenitor cell growth while impairing stem cell repopulation.

Authors:  Timothy B Campbell; Sunanda Basu; Giao Hangoc; Wen Tao; Hal E Broxmeyer
Journal:  Blood       Date:  2009-08-18       Impact factor: 22.113

4.  Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.

Authors:  Iris T Chan; Jeffery L Kutok; Ifor R Williams; Sarah Cohen; Lauren Kelly; Hirokazu Shigematsu; Leisa Johnson; Koichi Akashi; David A Tuveson; Tyler Jacks; D Gary Gilliland
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

5.  Effect of human activated NRAS on replication of delNS1 H5N1 influenza virus in MDCK cells.

Authors:  Jiping Zhu; HongBo Zhou; Wei Zou; MeiLin Jin
Journal:  Virol J       Date:  2011-05-19       Impact factor: 4.099

6.  Identification of Chemoresistance-Associated Key Genes and Pathways in High-Grade Serous Ovarian Cancer by Bioinformatics Analyses.

Authors:  Yong Wu; Lingfang Xia; Qinhao Guo; Jun Zhu; Yu Deng; Xiaohua Wu
Journal:  Cancer Manag Res       Date:  2020-06-30       Impact factor: 3.989

7.  Determination of Ras-GTP and Ras-GDP in patients with acute myelogenous leukemia (AML), myeloproliferative syndrome (MPS), juvenile myelomonocytic leukemia (JMML), acute lymphocytic leukemia (ALL), and malignant lymphoma: assessment of mutational and indirect activation.

Authors:  D Raepple; F von Lintig; T Zemojtel; M Duchniewicz; A Jung; M Lübbert; G R Boss; J S Scheele
Journal:  Ann Hematol       Date:  2008-09-11       Impact factor: 3.673

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.